Johnson & Johnson

In April 2010, Johnson & Johnson announced a massive recall of 43 over-the-counter children's medicines — including Tylenol, Motrin, Zyrtec, and Benadryl — from its McNeil Consumer Healthcare division. The recall, one of the largest OTC drug recalls in history, was triggered by FDA findings of contaminated ingredients, manufacturing equipment not cleaned between production runs, and a manufacturing process the FDA described as "not in control." Subsequent inspections found thick dust and grime contamination at McNeil's Fort Washington, Pennsylvania facility. The financial impact was immediate: OTC Consumer segment sales fell by more than 40% year-over-year in the quarter following the recall. The FDA shut down two McNeil manufacturing facilities. J&J's reputation in consumer health — its most profitable segment on a per-unit basis — was severely damaged.

J&J undertook a comprehensive manufacturing quality remediation program from 2010–2013:

• Capital investment: J&J invested more than $100 million in new manufacturing equipment, facility upgrades, and contamination control systems at McNeil's facilities — one of the largest pharmaceutical quality remediation investments in OTC drug history.
• Organizational restructuring: McNeil Consumer Healthcare was placed under direct reporting to J&J's CEO (bypassing the Consumer sector president) during the remediation, elevating quality oversight to the highest organizational level.
• Consent decree compliance: J&J operated under an FDA consent decree for McNeil's facilities, which required independent expert oversight of all manufacturing quality systems. The consent decree process forced documentation and standardization of quality procedures that had been inconsistent.
• Quality management system standardization: J&J implemented centralized quality standards across all Consumer segment manufacturing sites (not just McNeil), applying lessons from the McNeil remediation to reduce the risk of similar incidents elsewhere.
• Third-party manufacturing transition: For some product lines, J&J shifted production to FDA-inspected third-party manufacturers during the remediation period, ensuring supply continuity while internal plants were upgraded.
• Supply reliability restoration: J&J's Consumer segment built enhanced inventory buffers and supplier qualification processes to ensure supply continuity through future quality incidents.